Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Sevoflurane
Drug ID BADD_D02015
Description Sevoflurane, also called fluoromethyl, is an ether inhalation anaesthetic agent used for the induction and maintenance of general anesthesia. It is a volatile, non-flammable, non-irritant, and easy-to-administer compound with a low solubility profile and blood-to-gas partition coefficient.
Indications and Usage Used for induction and maintenance of general anesthesia in adult and pediatric patients for inpatient and outpatient surgery.
Marketing Status approved; vet_approved
ATC Code N01AB08
DrugBank ID DB01236
KEGG ID D00547
MeSH ID D000077149
PubChem ID 5206
TTD Drug ID D0W6ZF
NDC Product Code 12164-009; 10019-653; 0074-4456; 0781-6160; 66794-012; 54122-4486; 66794-015; 66794-022; 10019-651; 12164-005; 42677-110; 57884-0036; 10019-655; 10019-657
UNII 38LVP0K73A
Synonyms Sevoflurane | Fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl Ether | Fluoromethyl Hexafluoroisopropyl Ether | Sevorane | Ultane | BAX 3084
Chemical Information
Molecular Formula C4H3F7O
CAS Registry Number 28523-86-6
SMILES C(OC(C(F)(F)F)C(F)(F)F)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Nephrogenic diabetes insipidus14.05.07.002; 20.05.03.0100.000893%-
Nervous system disorder17.02.10.001---
Nervousness19.06.02.003---
Neuromyopathy15.05.03.010; 17.05.03.0030.000268%-
Oedema08.01.07.006; 14.05.06.010---
Oliguria20.01.03.004---
Pain08.01.08.004--
Pancreatitis07.18.01.001--
Papilloedema06.09.02.002; 17.07.02.004; 24.03.07.0010.000268%
Pharyngitis07.05.07.004; 11.01.13.003; 22.07.03.004--
Pneumothorax22.05.02.0030.000179%
Premature baby18.04.02.0010.000179%-
Pruritus23.03.12.001--
Pulmonary alveolar haemorrhage22.01.02.005; 24.07.01.0150.001072%-
Pulmonary oedema02.05.02.003; 22.01.03.0030.000536%
Pyrexia08.05.02.0030.001107%
Rash23.03.13.001---
Renal failure20.01.03.005---
Respiratory depression17.02.05.047; 22.02.01.0100.000268%-
Respiratory distress22.02.01.0120.000268%-
Respiratory failure14.01.04.003; 22.02.06.0020.000750%
Rhabdomyolysis15.05.05.0020.000447%
Salivary hypersecretion07.06.01.009---
Seizure17.12.03.0010.001697%
Shock24.06.02.002---
Skin disorder23.03.03.007---
Skin odour abnormal23.03.03.0120.000607%
Somnolence17.02.04.006; 19.02.05.003--
Sputum increased22.02.03.007---
Stridor22.04.02.003--
The 5th Page    First    Pre   5 6 7    Next   Last    Total 7 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene